Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD.

BACKGROUND AND OBJECTIVES eGFR and albuminuria primarily reflect glomerular function and injury, whereas tubule cell atrophy and interstitial fibrosis on kidney biopsy are important risk markers for CKD progression. Kidney tubule injury markers have primarily been studied in hospitalized AKI. Here, we examined the association between urinary kidney tubule injury markers at baseline with subsequent loss of kidney function in persons with nondiabetic CKD who participated in the Systolic Blood Pressure Intervention Trial (SPRINT). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Among 2428 SPRINT participants with CKD (eGFR<60 ml/min per 1.73 m2) at baseline, we measured urine markers of tubule injury (IL-18, kidney injury molecule-1 [KIM-1], neutrophil gelatinase-associated lipocalin [NGAL]), inflammation (monocyte chemoattractant protein-1 [MCP-1]), and repair (human cartilage glycoprotein-40 [YKL-40]). Cox proportional hazards models evaluated associations of these markers with the kidney composite outcome of 50% eGFR decline or ESKD requiring dialysis or kidney transplantation, and linear mixed models evaluated annualized change in eGFR. RESULTS Mean participant age was 73±9 (SD) years, 60% were men, 66% were white, and mean baseline eGFR was 46±11 ml/min per 1.73 m2. There were 87 kidney composite outcome events during a median follow-up of 3.8 years. Relative to the respective lowest quartiles, the highest quartiles of urinary KIM-1 (hazard ratio, 2.84; 95% confidence interval [95% CI], 1.31 to 6.17), MCP-1 (hazard ratio, 2.43; 95% CI, 1.13 to 5.23), and YKL-40 (hazard ratio, 1.95; 95% CI, 1.08 to 3.51) were associated with higher risk of the kidney composite outcome in fully adjusted models including baseline eGFR and urine albumin. In linear analysis, urinary IL-18 was the only marker associated with eGFR decline (-0.91 ml/min per 1.73 m2 per year for highest versus lowest quartile; 95% CI, -1.44 to -0.38), a finding that was stronger in the standard arm of SPRINT. CONCLUSIONS Urine markers of tubule cell injury provide information about risk of subsequent loss of kidney function, beyond the eGFR and urine albumin.

[1]  L. Fried When Increase in Serum Creatinine Doesn't Imply Kidney Damage. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[2]  A. Cheung,et al.  Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  C. Cannon,et al.  Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[4]  Keith C. Norris,et al.  Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review , 2018, BMC Nephrology.

[5]  Jackson T. Wright,et al.  Effects of Intensive BP Control in CKD. , 2017, Journal of the American Society of Nephrology : JASN.

[6]  N. Buus,et al.  Urine liver fatty acid binding protein and chronic kidney disease progression , 2017, Scandinavian journal of clinical and laboratory investigation.

[7]  F. Thomé,et al.  Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl-β-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes , 2017, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[8]  A. Levey,et al.  Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  L. Cantley,et al.  YKL-40 Associates with Renal Recovery in Deceased Donor Kidney Transplantation. , 2017, Journal of the American Society of Nephrology : JASN.

[10]  E. Siew,et al.  Biomarkers for the Early Detection and Prognosis of Acute Kidney Injury. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[11]  R. Vasan,et al.  Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. , 2017, Kidney international.

[12]  S. Nakagawa [Identification of Biomarkers for Tubular Injury and Interstitial Fibrosis in Chronic Kidney Disease]. , 2017, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[13]  Mardge H. Cohen,et al.  Use of urine biomarker-derived clusters to predict the risk of chronic kidney disease and all-cause mortality in HIV-infected women. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  Sudhir V. Shah,et al.  Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[15]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[16]  R. Vasan,et al.  Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[17]  D. Siscovick,et al.  Urine Collagen Fragments and CKD Progression-The Cardiovascular Health Study. , 2015, Journal of the American Society of Nephrology : JASN.

[18]  B. Teo,et al.  Normalisation of urinary biomarkers to creatinine for clinical practice and research--when and why. , 2015, Singapore medical journal.

[19]  Walter T Ambrosius,et al.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT) , 2014, Clinical trials.

[20]  R. Vasan,et al.  Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus , 2014, Diabetologia.

[21]  H. Feldman,et al.  Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease , 2013, Kidney international.

[22]  T. Olesen,et al.  Systolic Blood Pressure Intervention Trial (SPRINT) , 2013 .

[23]  D. Siscovick,et al.  Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  A. Köttgen,et al.  Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the Atherosclerosis Risk in Communities (ARIC) Study. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[26]  I. D. de Boer,et al.  Urinary Creatinine Excretion Rate and Mortality in Persons With Coronary Artery Disease: The Heart and Soul Study , 2010, Circulation.

[27]  Y. Iwamoto,et al.  Higher Levels of Urinary Albumin Excretion Within the Normal Range Predict Faster Decline in Glomerular Filtration Rate in Diabetic Patients , 2009, Diabetes Care.

[28]  D. Bolignano,et al.  Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[29]  A. Howie,et al.  Prognostic value of simple measurement of chronic damage in renal biopsy specimens. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  菊池 太朗,et al.  ラット椎間板皮下吸収モデルにおけるMCP-1(monocyte chemoattractant protein-1)の動向について , 1996 .

[31]  K. Nath,et al.  Tubulointerstitial changes as a major determinant in the progression of renal damage. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  J. Kassirer,et al.  Clinical evaluation of kidney function--glomerular function. , 1971, The New England journal of medicine.